NCT03632291View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

January 19, 2021

Study Completion Date

January 19, 2021

Conditions

Urticaria Chronic

Interventions

BIOLOGICAL

UB-221

UB-221 (75 mg/ml)

Trial Locations (2)

100

National Taiwan University Hospital, Taipei

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

lead

United BioPharma

INDUSTRY